Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAT2 | Q10469 | 2/20 | 0.46 |
| ▸ | GCGR | P47871 | 16/20 | 0.44 |
| ▸ | GIPR | P48546 | 8/20 | 0.41 |
| ▸ | ADCY8 | P40145 | 2/20 | 0.39 |
| ▸ | ADCY1 | Q08828 | 2/20 | 0.39 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.39 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.39 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.39 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.39 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.39 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.39 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.39 |
| ▸ | GCG | P01275 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087840 | 0.90 | MGAT2 (0.45) | MGAT2GCGRGIPRADCY8ADCY1 | |
| SCHEMBL4091781 | 0.84 | GCGR (0.43) | MGAT2GCGRGIPR | |
| SCHEMBL4086679 | 0.84 | MGAT2 (0.42) | MGAT2GCGRGIPRADCY8ADCY1 | |
| SCHEMBL4085309 | 0.83 | GCGR (0.51) | GCGRGIPRADCY8ADCY1ADCY6 | |
| SCHEMBL4086686 | 0.83 | GCGR (0.57) | MGAT2GCGRGIPRGCG | |
| SCHEMBL4082123 | 0.82 | GCGR (0.47) | MGAT2GCGRGIPR | |
| SCHEMBL4097437 | 0.82 | S1PR2 (0.40) | MGAT2GCGRGIPRADCY8ADCY1 | |
| SCHEMBL4091306 | 0.80 | MGAT2 (0.42) | MGAT2GCGRGIPRADCY8ADCY1 | |
| SCHEMBL4091679 | 0.80 | GCGR (0.52) | MGAT2GCGRGIPRADCY8ADCY1 | |
| SCHEMBL4096175 | 0.79 | MGAT2 (0.40) | MGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | MGAT2 149/4885GCGR 3/4885GIPR 4/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | MGAT2 149/4885GCGR 3/4885GIPR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.